M

Moderna

Develops mRNA-based medicines for health

Finance Strategy & Integration Leader

Full-TimeUpdated on 10/22/2026Deadline 1/11/27
$224.9k - $404.6k+ Annual discretionary bonus + Other incentive compensation + Equity award
Expert
Bachelor's
Cambridge, MA, USA
Hybrid70% in-office work model.
Finance & BankingCorporate Finance & FP&A

About the job

Requirements
  • A bachelor's degree in Finance, Accounting, Business, Economics, or a related field.
  • At least 15 years of progressive Finance experience, including significant experience in financial planning and analysis, strategic finance, business partnership, and/or financial operations.
  • Significant pharmaceutical or biotechnology industry experience.
  • Demonstrated experience leading complex, enterprise-level financial planning, forecasting, reporting, and analytical processes.
  • Deep financial modeling and analytical expertise, including integrating complex operational and financial assumptions into short- and long-term outlooks.
  • Demonstrated success influencing senior leaders and leading across a matrixed organization without relying on direct authority.
  • Experience partnering with senior business and Finance executives on strategic decisions, investments, risks, and trade-offs.
  • Strong executive communication and presentation skills, including distilling complex financial and operational topics into clear insights, recommendations, and decision points.
  • Demonstrated ability to independently lead complex cross-functional initiatives involving multiple stakeholders, dependencies, and organizational boundaries.
Responsibilities
  • Serve as the senior Finance representative on the INT Leadership Team, contributing financial perspective to strategic, operational, and investment discussions.
  • Provide dotted-line leadership to Finance partners supporting INT Commercial & Medical, Research & Development, and CMC; lead cross-functional Finance discussions to align assumptions and create a unified financial narrative for INT.
  • Translate evolving INT strategy and business priorities into financial implications and ensure Finance planning reflects leadership decisions.
  • Provide senior leadership and continuity across INT Finance while enabling the Head of CMC & INT Finance to span responsibilities across INT and other organizational areas.
  • Lead integration of INT financial planning, forecasting, reporting, and performance management across CMC, Commercial & Medical, Research & Development, and other relevant areas.
  • Develop and maintain a consolidated financial view of INT with consistent assumptions, methodologies, timelines, and definitions across functional Finance teams.
  • Drive scenario and sensitivity analysis to inform strategic choices, resource allocation, and business trade-offs.
  • Synthesize complex financial and operational information into executive-ready insights for the INT Leadership Team, Finance leadership, and other senior stakeholders.
  • Ensure connectivity between INT financial planning and broader Moderna Finance processes, including Corporate FP&A and other relevant Finance organizations.
  • Own the consolidated INT financial model as an individual contributor, including short-term forecasting, long-range planning, and ongoing performance reporting.
  • Establish model governance, including ownership of assumptions, change controls, scenario management, documentation, and reconciliation.
  • Evolve the model to reflect business changes, improve forecast accuracy, and support increasingly sophisticated financial and operational analysis.
  • Use the model to surface sensitivities, trade-offs, risks, and opportunities for senior INT and Finance leadership.
  • Lead the Finance readiness workstream for INT commercial go-live, preparing the Finance organization to support commercialization operationally and financially.
  • Establish and manage an integrated Finance readiness plan covering activities, dependencies, milestones, decisions, and risks required for commercial launch.
  • Partner with Commercial, Supply Chain, Digital, and other business functions to identify Finance requirements from the evolving commercial operating model and ensure they are addressed before go-live.
  • Maintain a consolidated view of Finance readiness for the Head of CMC & INT Finance and senior leaders, highlighting status, critical decisions, emerging risks, and areas requiring leadership intervention.
  • Coordinate with Merck on Finance readiness activities dependent on cross-company processes, data flows, operating assumptions, systems, or governance.
  • Transition newly established processes and capabilities into sustainable business-as-usual ownership following commercial go-live, with clear accountability and effective handoffs across Finance.
  • Serve as a senior Finance counterpart to Merck on INT financial, operational, and strategic matters.
  • Engage with Merck Finance and business leadership to align on forecasts, assumptions, financial performance, planning processes, and business drivers.
  • Support financial aspects of alliance governance and strategic discussions, ensuring Moderna leadership understands financial implications and areas requiring alignment.
  • Lead resolution of complex cross-company financial topics and coordinate Moderna stakeholders when broader organizational input is required.
  • Build credible relationships with Merck counterparts and establish effective, scalable Finance ways of working across the alliance.
  • Provide Moderna Finance leadership with transparency into emerging alliance topics, risks, opportunities, and decisions.
  • Ensure relevant Merck assumptions and inputs are incorporated into INT financial forecasts and leadership reporting.
  • Independently lead complex, high-impact financial workstreams across INT.
  • Create structure and clarity where processes, ownership, or operating models are evolving.
  • Anticipate emerging business and financial needs and proactively develop analyses, processes, and decision frameworks.
  • Drive standardization and continuous improvement across INT forecasting, reporting, modeling, and analytical processes.
  • Strengthen the quality, consistency, and usability of financial information across INT.
  • Build connectivity between INT Finance and CMC Finance, Commercial Finance, R&D Finance, Corporate FP&A, Accounting, Digital Finance, Supply Chain Finance, and other relevant parts of Moderna Finance.
  • Identify opportunities to improve forecasting accuracy, reporting quality, financial controls, data transparency, and cycle times.
  • Lead through influence, judgment, credibility, and relationships rather than direct reporting authority.
Desired Qualifications
  • Experience supporting a commercial-stage pharmaceutical or biotechnology business with significant CMC, R&D, and commercial complexity.
  • Experience operating within an alliance, partnership, joint-development, or joint-commercialization model.
  • Experience supporting commercial launch readiness or establishing Finance capabilities for a new product or commercialization model.
  • Demonstrated ability to lead and integrate Finance teams across multiple functional areas.
  • Strong understanding of pharmaceutical financial and operational drivers across development, manufacturing, supply, commercialization, and lifecycle management.
  • Business acumen, including the ability to challenge assumptions, connect financial and non-financial drivers, and understand strategic implications.
  • Judgment and comfort making decisions and recommendations amid ambiguity, incomplete information, and competing priorities.
  • Ability to build credibility and trusted relationships with senior internal and external stakeholders.
  • Experience developing scalable planning, reporting, governance, and operating processes in rapidly evolving organizations.
  • Ability to balance strategic thinking with attention to financial detail and execution.
  • Track record of independently identifying issues, mobilizing stakeholders, and driving complex matters through to resolution.
  • Experience with Oracle planning and reporting tools, including EPM/Essbase.

About the company

Moderna develops medicines built on messenger RNA (mRNA). Its products use mRNA delivered into cells to instruct them to produce specific proteins that can prevent or treat disease, with vaccines being a primary example. In practice, a dose delivers engineered mRNA into the body, cells translate it into a target protein, and the immune system responds or the protein modulates biology to combat disease. Moderna differentiates itself through its focus on building a whole mRNA medicines platform and in-house capabilities for designing, manufacturing, and scaling mRNA therapies, including rapid development and large-scale production. Its goal is to create a new category of medicines based on mRNA that can improve how diseases are discovered, developed, and treated, ultimately improving patient outcomes.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2010

Get referred to Moderna

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 2026 convertible notes raised $3 billion for oncology growth and debt flexibility.
  • April 21, 2026 European Commission approval made mCombriax the first authorized flu-COVID combo vaccine.
  • Second-quarter 2026 guidance targets up to 10% revenue growth and year-end cash of $4.7 billion.

What critics are saying

  • September 28, 2026, Delaware kept Bayer's mRNA patent case alive against Moderna.
  • July 15, 2026, Sanofi sued Moderna over COVID vaccine patents in New Jersey.
  • If intismeran fails beyond melanoma, Moderna remains a shrinking vaccine company.

What makes Moderna unique

  • Moderna's mRNA platform spans vaccines, oncology, and rare disease, unlike one-product peers.
  • September 30, 2026, Moderna added a COO to scale intismeran autogene manufacturing.
  • Bancel says Moderna owns mutation-selection software for personalized vaccines and synthetic, cell-free production.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Unlimited Paid Time Off
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Sabbatical Leave
  • Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Oct 21st, 2026
Moderna soars 600% to $90B market cap, but valuation leaves no margin for error

Moderna (NASDAQ: MRNA) has soared over 600% this year, making it the best performer among large-cap healthcare stocks. Eli Lilly gained 16% and Johnson & Johnson 22%. The rally followed US approval of mFLUSIVA, an influenza vaccine for people aged 50 and older. Moderna also said its personalised cancer vaccine, intismeran autogene, significantly improved recurrence-free survival in certain melanoma patients when combined with Merck's Keytruda. It is the first personalised vaccine to produce positive Phase 3 results. Moderna's market cap now stands at $90 billion. The average analyst price target of $123.61 implies a downside of about 45%. In the first six months of 2026, revenue rose 113.6% to $534 million, but net loss widened to $2.1 billion from $1.8 billion.

Yahoo Finance
Oct 21st, 2026
ServiceNow and Kinder Morgan are large-cap picks to watch; Moderna's $96.65B value underwhelms

StockStory, a stock research service, named two large-cap stocks to watch and one to avoid. It advises steering clear of Moderna, which has a market cap of $96.65 billion. Sales fell 20.5% annually over five years, and earnings per share dropped 24.5% annually. Its free cash flow margin fell 95.9 percentage points. The stock trades at $241.71, or 44.1x forward price-to-sales. ServiceNow ($154.6 billion market cap) grew annual recurring revenue 22.3% over the last year and has a free cash flow margin of 33.4%. It trades at $148.56 per share. Kinder Morgan ($74.75 billion market cap) reported $17.96 billion in revenue. Its shares trade at $33.64, or 22.5x forward earnings.

Yahoo Finance
Oct 19th, 2026
Moderna, Chemed and 10x Genomics: three healthcare stocks to avoid despite a 25.2% sector rally

Healthcare stocks have gained 25.2% over the past six months, beating the S&P 500 by 16.3 percentage points. Even so, StockStory warns that heavy regulation can hurt earnings, and names three stocks to avoid. Moderna, valued at $87.04 billion, has seen sales fall 20.5% a year over five years. Earnings per share dropped 24.5% annually, and the stock trades at 46x forward price-to-sales. Chemed, worth $6.67 billion, grew revenue 4.1% a year over five years, slower than its peers. Its adjusted operating margin fell 3.9 percentage points, and it trades at 20x forward earnings. 10x Genomics, valued at $9.10 billion, saw revenue decline 1.2% annually over two years to $616.9 million. Its returns on capital are negative.

CNBC
Oct 14th, 2026
Merck CEO expects Moderna cancer vaccine's six-week production time to shorten

Merck chief executive officer Rob Davis expects the company's personalised cancer vaccine with Moderna to become faster to make over time. He told CNBC the current timeline is six weeks, from sequencing a patient's tumour to delivering the shot to the hospital. "I do think over time you're going to see that timeline shortened," Davis said. For now, the focus is on readying supply and the market. The vaccine targets the mutations in each patient's tumour and is paired with Merck's immunotherapy Keytruda. In August, the companies released positive initial late-stage data in melanoma patients. Trials are also under way in lung, bladder, and kidney cancers. Davis spoke as Merck opened its 120,000-square-foot research facility, Advance, in West Point, Pennsylvania.

The Hindu BusinessLine
Oct 14th, 2026
AI cannot replace clinical trials soon, warns Moderna co-founder Noubar Afeyan.

AI cannot replace clinical trials soon, warns Moderna co-founder Noubar Afeyan. Afeyan cautioned against overhyping AI's ability to cure diseases such as cancer, arguing that scientific progress must be accompanied by greater humility about what researchers understand about human physiology. Updated - October 14, 2026 at 01:03 PM. Noubar Afeyan, co-founder and chairman of Moderna In | Photo Credit: Bloomberg/ANINDITO MUKHERJEE Artificial intelligence (AI) could transform scientific discovery and accelerate drug development, but replacing clinical trials with digital simulations remains a distant prospect given the complexity of human biology, Noubar Afeyan, co-founder and chairman of Moderna, said at the Bloomberg New Economy Forum in New Delhi on Tuesday. Afeyan cautioned against exaggerated claims about AI's potential to cure diseases such as cancer, arguing that scientific progress must be accompanied by greater humility about what researchers understand about human physiology. "I think the hardest thing will be to do what is out there these days in terms of speculation, which is simulating clinical trials and avoiding them altogether," he said. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.